Eicosanoids in inflammatory skin diseases

Prostaglandins and Other Lipid Mediators

Volumn 63, Issue 1-2, 2000, Pages 43-54

  Fogh, Karsten ^a   Kragballe, Knud ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSANOID; LEUKOTRIENE; LIPOXYGENASE;

ATOPIC DERMATITIS; FATTY ACID SYNTHESIS; HUMAN; HUMAN TISSUE; ICOSANOID METABOLISM; LIPID ANALYSIS; PATHOGENESIS; PSORIASIS; REVIEW; SKIN INFLAMMATION;

EID: 0033763353     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(00)00096-4     Document Type: Article

References (96)

1. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes
2. 4 toward rabbit neutrophils
3. 4 increase calcium sodium influxes in rabbit neutrophils
4. 4: A mediator of vascular permeability
5. 4 to receptors on human polymorphonuclear leukocytes
6. 4 stimulate DNA synthesis in cultured human epidermal keratinocytes
7. Melanocyte-stimulating properties of arachidonic acid metabolites: Possible role in postinflammatory pigmentation
8. 4-induced human melanocyte growth are inhibited by different isoquinolinesulfonamides
9. 4)
10. 4 possess different biological potencies
11. 4 and its omega-oxidation products
12. 4 and its omega-oxidation products
13. 4
14. 4
15. 4) in human skin
16. 2 in human skin
17. Stimulus specificity of the chemotactic deactivation of human neutrophils by lipoxygenase products of arachidonic acid
18. 4
19. 4
20. 4
21. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules in vivo effects with relevance to the acute inflammatory response
22. 4 on cutaneous blood flow in humans
23. 4
24. Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge
25. 4 in allergic rhinitis
26. Stereochemical difference between 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) in platelets and psoriatic lesions
27. Proinflammatory effects of 12(R)-hydroxy-5,8,10,14-eicosatetraenoic acid in human skin
28. Stimulated platelet aggregation and abnormal arachidonic acid metabolism in psoriasis
29. 12(R)-hydroxy-5,8,10,14-eicosatetraenoic acid is a chemoattractant for polymorphonuclear leukocytes in vitro
30. 4) in psoriasis and normal human skin
31. 2 in rat and human skin
32. Cutaneous reactions to intradermal prostaglandins
33. Evidence in man of synergistic interactions between putative mediators of acute inflammation and asthma
34. 2 to membrane preparations from human skin: Receptor modulation by UVB-irradiation and chemical agents
35. Regulation of the immune response by prostaglandins
36. Mediators and modulators of human lymphocyte chemotaxis
37. Prostaglandins as endogenous mediators of IL-1 production
38. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid
39. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages
40. 4-induced neutrophil chemotaxis by 15-hydroxy-eicosatetraenoic acid (15-HETE)
41. Modulation of eicosanoid formation by lesional skin of psoriasis skin. An ex vivo skin model
42. 4-induced skin response
43. 4)
44. Hydroperoxyeicosatetraenoic acids: Potent inhibitors of lymphocyte responses
45. Effect of lipocyclooxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets
46. The role of arachidonic acid metabolism in the activities of interleukin 1 and 2
47. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase
48. IL-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: In vitro anti-inflammatory effects by IL-4 and IL-10, but not by IL-1 receptor antagonist protein
49. Interleukin 13 suppresses cytokine production and stimulates the production of 15-HETE in PBMC
50. 4-like material in biologically active amounts from lesional skin of patients with psoriasis
51. Identification af chemotactic lipoxygenase products of arachidonate metabolism in psoriasis
52. Skin levels of arachidonic acid derived inflammatory mediators and histamine in atopic dermatitis and psoriasis
53. 4 and D 412 in psoriatic skin lesions
54. Enhanced synthesis of cysteinyl leukotrienes in psoriasis
55. 4, but not 12-HETE is present in biologically active amounts in acute guttate lesions
56. 5-lipoxygenase activation in psoriasis: A dead issue?
57. 4-like chemotactic arachidonate metabolites from human keratinocytes
58. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease
59. Biosynthesis of lipoxygenase products by enzyme preparations from normal and psoriatic skin
60. 4 hydrolase
61. 4 into peptide leukotrienes: Possible role in transcellular metabolism
62. 4 by transcellular biosynthesis
63. 4-hydrolase activity in human epidermis
64. 4 hydrolase activity in human lymphocytes and human skin
65. 4 hydrolase in human skin
66. 4 hydrolase from human epidermis
67. 4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes
68. 4 hydrolase in the pathogenesis of psoriasis
69. 4 receptor antagonist with anti-inflammatory activity
70. Cyclosporine improves psoriasis in a double-blind study
71. 4 hydrolase level in human keratinocyte cultures
72. Cyclosporin A inhibits leukotriene production in intact RBL-1 cells without inhibiting leukotriene biosynthetic enzymes
73. 2 and of 12-hydroxy-5,8,10,14-eicosatetraenoic acid in epidermis of psoriasis: Evidence of perturbed regulation of arachidonic acid levels in psoriasis
74. The identification of hydroxy fatty acids in psoriatic skin
75. Heterogenous distribution of lipoxygenase products in psoriatic skin lesions
76. Dermis derived 15-hydroxy-eicosatetraenoic acid inhibits epidermal 12-lipoxygenase activity
77. Selective decrease of 15-hydroxy-eicosatetraenoic acid (15-HETE) formation in uninvolved psoriatic dermis
78. Improvement of psoriasis vulgaris after intralesional injections of 15-hydroxyeicosatetraenoic acid (15-HETE)
79. Selective incorporation of HETEs into epidermal phospholipids
80. Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques
81. Distribution of monohydroxy fatty acids in specific human epidermal phospholipids
82. Monohydroxy fatty acids esterified to phospholipids are decreased in lesional psoriatic skin
83. Studies and perspectives of signal transduction in the skin
84. Incorporation of 13-hydroxyoctadecadienoic acid (13-HODE) into epidermal ceramides and phospholipids: Phospholipase C-catalyzed release of novel 13-HODE-containing diacylglycerol
85. Expression of protein kinase C isoenzymes in guinea pig epidermis: Selective inhibition of PKC-b activity by 13-hydroxyoctadecadienoic acid-containing diacylglycerol
86. 13-hydroxyoctadecadienoic acid reverses epidermal hyperproliferation via selective inhibition of protein kinase C-b activity
87. Histamine and allergic diseases
88. 4 are present in biologically active concentrations
89. Synergistic interactions between prostaglandins and Paf-acether in experimental animals and man
90. Enhanced leukotriene synthesis in leukocytes of atopic dermatitis and asthmatic subjects
91. IL-3, IL-8, FMLP, and C5a enhance the release of leukotrienes from patients with atopic dermatitis
92. 4 hydrolase by neutrophils and platelets from patients with atopic dermatitis
93. 4 in patients with atopic dermatitis and other skin diseases: Changes by an anti-allergic agent, azelastine hydrochloride
94. 4 hydrolase in peripheral leukocytes of patients with atopic dermatitis
95. 4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis
96. A pilot study examining the role of zileuton in atopic dermatitis